Skip to main content

Entresto Side Effects

Generic name: sacubitril / valsartan

Medically reviewed by Drugs.com. Last updated on Mar 2, 2023.

Note: This document contains side effect information about sacubitril / valsartan. Some dosage forms listed on this page may not apply to the brand name Entresto.

Applies to sacubitril / valsartan: oral tablet.

Warning

Oral route (Tablet)

Drugs that act directly on the renin-angiotensin system may cause fetal injury or death. Discontinue use immediately if pregnancy is detected.

Serious side effects of Entresto

Along with its needed effects, sacubitril/valsartan may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking sacubitril / valsartan:

More common

Less common

Rare

Other side effects of Entresto

Some side effects of sacubitril / valsartan may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to sacubitril / valsartan: oral tablet.

General

The most common adverse reactions were hypotension, hyperkalemia, cough, dizziness, and renal failure.[Ref]

Cardiovascular

Very common (10% or more): Hypotension (18%)

Common (1% to 10%): Orthostasis[Ref]

Metabolic

Very common (10% or more): Potassium greater than 5.5 mEq/L (16%), hyperkalemia (12%)[Ref]

Renal

Very common (10% or more): Serum creatinine increased greater than 50% (16%)

Common (1% to 10%): Renal failure/acute renal failure[Ref]

Respiratory

Common (1% to 10%): Cough[Ref]

Nervous system

Common (1% to 10%): Dizziness[Ref]

Dermatologic

Uncommon (0.1% to 1%): Angioedema

Postmarketing reports: Rash, pruritus[Ref]

The incidence of angioedema was 2.4% in Black patients.[Ref]

Hematologic

Common (1% to 10%): Hemoglobin/hematocrit decreased greater than 20%[Ref]

Other

Common (1% to 10%): Falls[Ref]

Immunologic

Postmarketing reports: Hypersensitivity, anaphylactic reaction

Frequently asked questions

References

1. Product Information. Entresto (sacubitril-valsartan). Novartis Pharmaceuticals. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.